Chronic Lymphocytic Leukemia

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Jennifer R. Brown, MD, PhD presents an interim analysis from the ALPINE study of zanubrutinib vs. ibrutinib in patients with R/R CLL/SLL presented at the 2021 European Hematology Association virtual congress.

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).

William Wierda, MD, PhD, leads a panel of experts in a discussion pertaining to the treatment of chronic lymphocytic leukemia (CLL), beginning with the evolving treatment landscape.

Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Fixed-duration venetoclax plus obinutuzumab demonstrated prolonged remissions compared with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Pirtobrutinib produced promising efficacy in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, those with mantle cell lymphoma and other non-Hodgkin lymphomas, and those who progressed on Richter transformation–directed therapy.

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Tanya Siddiqi, MD, discusses the role of acalabrutinib as a frontline treatment for patients with chronic lymphocytic leukemia.

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.